Trials / Recruiting
RecruitingNCT06345716
Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,500 (estimated)
- Sponsor
- University of Monastir · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomized, single-blind study. Patients included in the study after successful treatment of the acute attack were randomized upon discharge from the Emergency Department into three groups: oral paracetamol-tramadol group, oral paracetamol-caffeine group and oral placebo group.
Detailed description
This is a prospective, randomized, single-blind study. Patients included in the study after successful treatment of the acute attack were randomized upon discharge from the Emergency Department into three groups: oral paracetamol-tramadol group, oral paracetamol-caffeine group and oral placebo group. Different parameters are collected on a standard form prepared for all cases of renal colic included in our study. This sheet essentially contains: Temperature, systolic and diastolic blood pressure, heart rate, pain intensity assessed by VAS, abdominal tenderness as well as the existence of Giardano signs. Additional examinations were not systematically carried out for all patients: AUSP, ECBU, renal ultrasound, creatinemia and blood sugar. Their realization depended on the clinical context. The use of imaging was done following the indications specified in the text of the consensus of the French Society of Emergency Medicine (updated in 2008)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paracétamol tramadol | Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days |
| DRUG | Paracétamol cafeine | Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days |
| DRUG | Placebo | Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days |
Timeline
- Start date
- 2024-04-10
- Primary completion
- 2025-03-15
- Completion
- 2025-11-30
- First posted
- 2024-04-03
- Last updated
- 2024-09-19
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT06345716. Inclusion in this directory is not an endorsement.